Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
Overview of AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.
Core Business Areas
AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.
Research, Development, and Collaborations
At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.
Operational Excellence and Strategic Positioning
AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.
Market Significance and Competitive Landscape
The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.
Scientific Rigor and Clinical Expertise
Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.
Conclusion
Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.
AIM ImmunoTech (NYSE: AIM) has reported its Q4 and full year 2024 financial results, highlighting progress in its Ampligen clinical development programs. The company ended 2024 with $4.0 million in cash and investments, down from $13.1 million in 2023. Financial metrics show reduced expenses, with R&D costs decreasing to $6.2 million from $10.9 million and G&A expenses dropping to $13.7 million from $21.1 million year-over-year.
Key developments include the advancement of the DURIPANC Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, and upcoming milestones in multiple clinical trials through 2026. The company is also pursuing studies in refractory melanoma, triple negative breast cancer, and advanced recurrent ovarian cancer, with several trials being partially funded by collaborators including AstraZeneca and Merck.
AIM ImmunoTech (NYSE American: AIM) participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference on March 11, 2025. CEO Thomas K. Equels presented five key focus areas for 2025:
- Progress in late-stage pancreatic cancer treatment through the Phase 1b/2 DURIPANC trial at Erasmus Medical Center, Netherlands
- Expanded research in ME/CFS and post-COVID conditions
- Advancement of oncology pipeline with trials reaching major milestones
- Development of Ampligen as a vaccine adjuvant for bird flu
- Ampligen's potential as a broad-spectrum immunotherapy
The presentation is available on-demand through the company's website and investor events page.
AIM ImmunoTech has announced that Dr. Paul Goepfert from the University of Alabama-Birmingham will lead a planned clinical study combining Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. This follows a previous UAB trial where Ampligen, used as a vaccine adjuvant, increased immune response to seasonal variants by over 4-fold and induced cross-reactive protection against highly pathogenic avian influenza strains H5N1, H7N9, and H7N3.
The company has engaged Amarex Clinical Research to prepare an Investigational New Drug application and manage the clinical study. AIM is seeking industry or governmental grants for study funding, with CEO Thomas K. Equels highlighting the potential cost-effectiveness of this approach at approximately $10 million in development costs compared to potentially billions for new mRNA vaccine development.
AIM ImmunoTech (NYSE American: AIM) has received acceptance from the NYSE American for its compliance plan to meet minimum stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. The company has been granted until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards. CEO Thomas K. Equels expressed satisfaction with the approval and mentioned ongoing developments in the company's oncology and antiviral pipelines.
AIM ImmunoTech (NYSE American: AIM) has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately. Chemerow brings over 40 years of finance, accounting, and operations leadership experience to the role.
Chemerow previously served as CFO, Treasurer, and Chief Revenue Officer at Comscore, and as COO and CFO of Rentrak until its 2016 merger with Comscore. He currently serves on the Board of Directors for Dunham's Athleisure and the Advisory Board of Huntington Outdoor.
The appointment was unanimously approved by AIM's Board. Board Chairman William Mitchell highlighted Chemerow's proven track record of leadership and financial acumen as valuable additions to AIM's mission. Chemerow expressed optimism about AIM's position in the immuno-pharma space, particularly noting Ampligen's potential across various high-value indications.
AIM ImmunoTech (NYSE American: AIM) has dosed the first new subject in Phase 2 of their Phase 1b/2 clinical trial studying the combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) for treating late-stage pancreatic cancer. The trial, known as DURIPANC, is being conducted at the Erasmus Medical Center in the Netherlands.
Several subjects from Phase 1 who received the highest dose will also be included in Phase 2. The investigator-initiated, exploratory, open-label, single-center study expects to enroll up to 25 patients in the Phase 2 portion.
AIM CEO Thomas K. Equels expressed confidence in steady enrollment, noting that unlike many pancreatic cancer studies where accrual can be challenging, they expect consistent patient recruitment for this trial combining the TLR-3 agonist rintatolimod with the anti-PD-L1 immune checkpoint inhibitor durvalumab.
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor segment featuring CEO Thomas K. Equels and Professor Casper H.J. van Eijck from Erasmus Medical Center discussing their Phase 1b/2 clinical trial DURIPANC. The trial investigates the combination of AIM's Ampligen® and AstraZeneca's Imfinzi® for treating late-stage pancreatic cancer.
The Erasmus MC Safety Committee has approved advancing to Phase 2 after reviewing Phase 1 safety data, which showed the combination treatment was generally well-tolerated with no treatment-related severe adverse events or dose-limiting toxicities. The study is being conducted as an investigator-initiated, exploratory, open-label, single-center trial in the Netherlands at Erasmus MC.
AIM ImmunoTech (NYSE American: AIM) has announced it will postpone its planned offering under Registration Statement Form S-1. The company will not proceed with the offering until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
AIM ImmunoTech (NYSE American: AIM) has announced plans to advance Ampligen as a vaccine adjuvant for avian influenza. The company will conduct a follow-up clinical study combining Ampligen with AstraZeneca's FluMist nasal spray vaccine. This initiative builds on previous research at the University of Alabama-Birmingham, which showed that intranasal Ampligen administration after FluMist increased immune response by over four-fold and induced cross-reactive antibodies against highly pathogenic avian influenza strains H5N1, H7N9, and H7N3.
Pre-clinical studies demonstrated significant protective effects, with 50-100% survival rates against various H5N1 strains in mice. Non-human primate studies showed protection against H5N1 symptoms and generated neutralizing antibodies. Previous human trials indicated that intranasal Ampligen was generally well-tolerated with no serious treatment-related adverse events.
AIM ImmunoTech (NYSE American: AIM) has received Safety Committee approval to advance to Phase 2 of their Phase 1b/2 clinical trial studying the combination of Ampligen® and Imfinzi® for late-stage pancreatic cancer treatment. The approval follows positive Phase 1 safety data showing the combination therapy was generally well-tolerated with no severe treatment-related adverse events.
The DURIPANC study, conducted at Erasmus Medical Center in the Netherlands, will enroll up to 25 patients in Phase 2, including six patients from Phase 1. Early observations indicate improvements in quality of life, with some patients showing stable disease for 15+ months after starting FOLFIRINOX treatment. This is notable considering approximately 80% of similar patients at Erasmus MC typically show disease progression after three months without this treatment.
The study aims to address a significant unmet need in oncology, as pancreatic cancer claims approximately 50,000 American lives annually with currently no effective therapy available.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
What is the core focus of AIM ImmunoTech Inc.?
What are the main therapeutic products developed by AIM ImmunoTech?
How does AIM ImmunoTech position itself within the biopharmaceutical industry?
What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?
How does the company approach clinical research and product development?
What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?
